- QGEN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $17.7 million.
- QGEN has traded 402,609 shares today.
- QGEN is trading at 9.49 times the normal volume for the stock at this time of day.
- QGEN is trading at a new low 4.00% below yesterday's close.
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in QGEN with the Ticky from Trade-Ideas. See the FREE profile for QGEN NOW at Trade-Ideas More details on QGEN: QIAGEN N.V. provides sample to insight solutions that transform biological materials into valuable molecular insights worldwide. QGEN has a PE ratio of 4. Currently there are 4 analysts that rate Qiagen a buy, 1 analyst rates it a sell, and 9 rate it a hold. The average volume for Qiagen has been 860,300 shares per day over the past 30 days. Qiagen has a market cap of $5.0 billion and is part of the services sector and diversified services industry. The stock has a beta of 0.89 and a short float of 2.3% with 5.52 days to cover. Shares are down 22.3% year-to-date as of the close of trading on Monday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Qiagen as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, unimpressive growth in net income and weak operating cash flow. Highlights from the ratings report include:
- The current debt-to-equity ratio, 0.40, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 2.97, which clearly demonstrates the ability to cover short-term cash needs.
- QIAGEN NV's earnings per share declined by 25.0% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, QIAGEN NV increased its bottom line by earning $0.53 versus $0.49 in the prior year. This year, the market expects an improvement in earnings ($1.08 versus $0.53).
- The gross profit margin for QIAGEN NV is currently very high, coming in at 76.67%. Regardless of QGEN's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 4.98% trails the industry average.
- Reflecting the weaknesses we have cited, including the decline in the company's earnings per share, QGEN has underperformed the S&P 500 Index, declining 15.63% from its price level of one year ago. Looking ahead, we do not see anything in this company's numbers that would change the one-year trend. It was down over the last twelve months; and it could be down again in the next twelve. Naturally, a bull or bear market could sway the movement of this stock.
- The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Life Sciences Tools & Services industry average. The net income has decreased by 23.6% when compared to the same quarter one year ago, dropping from $19.49 million to $14.88 million.
- You can view the full Qiagen Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.